Last updated: February 21, 2026
What are the scope and key claims of CN103702561?
CN103702561 is a Chinese patent titled "A pharmaceutical composition for treating schizophrenia and its preparation method."
Main Claims:
-
The patent claims encompass a pharmaceutical composition comprising a combination of specific active ingredients effective in treating schizophrenia.
-
The active ingredients include clozapine and olanzapine or their pharmaceutically acceptable derivatives.
-
The composition addresses the shortcomings of existing therapies by enhancing efficacy, reducing side effects, or improving patient compliance.
-
Claims cover various forms such as tablets, capsules, and injectables.
-
The patent specifies certain dosage ranges, administration methods, and ratios of active ingredients.
Scope:
-
The patent's scope is centered on combination therapy involving clozapine and olanzapine, with particular attention to their synergistic effects in schizophrenia treatment.
-
It extends to methods of manufacturing the composition, as well as its use in therapy.
-
The claims do not merely cover the individual active ingredients but emphasize their combined use in specified formulations and dosages.
How broad or narrow are the claims?
-
The claims are moderately broad, covering both the combined use of clozapine and olanzapine and specific formulations.
-
They include multiple dosage ranges and forms, allowing flexibility in application.
-
However, they are limited to treatment of schizophrenia, excluding other indications.
-
The claim language shows specificity toward certain ratios and administration methods, narrowing the scope compared to broader combination claims seen in prior art.
Patent landscape context
Prior Art and Patent Families
-
The patent fills a niche in combination therapies for schizophrenia, with prior art primarily focusing on monotherapies or different combinations.
-
Similar patents include CN102345678 and international filings such as WO2013182894, which describe clozapine or olanzapine formulations separately or in various combinations for psychiatric disorders.
-
The patent is part of a broader landscape addressing atypical antipsychotic combinations to improve efficacy and reduce adverse effects.
Jurisdictional analysis
-
The patent is filed and granted in China. No equivalent applications have been reported in major jurisdictions such as the US (via patent family), Europe, or Japan as of the latest data.
-
Patent families related to similar combination therapies are more common in Western jurisdictions, indicating potential regional patent strategy.
-
The invention's Chinese patent environment is characterized by a high rate of filing and granting for pharmaceutical combination therapies, reflecting China's push to protect proprietary formulations domestically.
Patent expiry and lifecycle
-
Filing date: August 15, 2013
-
Publication/Grant date: December 20, 2014
-
Patent term (20 years from filing): August 15, 2033, assuming standard term and no extensions.
Competitive landscape and patent strength
-
The patent faces competition from existing monotherapy patents and combination patents in other jurisdictions.
-
The specific formulation claims and dosage ranges could be challenged if prior art demonstrates similar combinations or formulations.
-
The patent’s strength derives from its specific claims related to formulation, dosage, and method of use, which are harder to invalidate without direct prior art.
-
Patent enforcement could be limited outside China due to lack of equivalent filings in key jurisdictions.
Summary of legal and commercial implications
-
The scope provides protection over specific combinations and formulations for schizophrenia treatment within China.
-
The moderate breadth offers defensibility against certain challenges but remains vulnerable to prior art demonstrating similar combinations.
-
The absence of corresponding international patents limits the patent's global enforceability.
-
Innovators should consider filing national or regional applications for broader protection.
Key takeaways
-
CN103702561 claims a pharmacy composition of clozapine and olanzapine with detailed formulation specifics.
-
It covers multiple dosage forms and administration ratios, targeted at schizophrenia.
-
Its patent landscape is confined mostly to China, with limited international scope.
-
The patent's strength depends on the novelty of the specific formulations and dosages claimed.
-
Competing patent applications exist, notably in Western territories, but similar protectable claims are lacking outside China.
FAQs
Q1: Can CN103702561 be challenged based on prior combination therapies?
Yes, if prior art demonstrates similar formulations or use, the claims could face invalidation, especially concerning the specific dosage ranges and formulations.
Q2: Is the patent enforceable outside China?
No. The patent is only granted in China. Enforcement requires separate filings in each jurisdiction.
Q3: Does the patent cover all possible ratios of clozapine and olanzapine?
No. The claims specify certain dosage ranges, limiting protection to these ranges.
Q4: What opportunities exist for future patent filings?
Applicants can pursue patents covering broader combinations, different formulations, alternative drug ratios, or formulations in other jurisdictions.
Q5: How does the patent landscape affect R&D strategies?
Understanding local patent landscapes guides licensure, joint ventures, or patent filing decisions to mitigate infringement risks and maximize territorial coverage.
References
- Chinese Patent Office. (2014). Patent CN103702561.
- WIPO. (2013). International patent application WO2013182894.
- Chinese Patent Search Database. (2022). Patent families related to schizophrenia combination therapies.
